Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06249451
Other study ID # BB 140/23
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 22, 2024
Est. completion date April 23, 2025

Study information

Verified date January 2024
Source University Medicine Greifswald
Contact Lena Ulm
Phone 00493834865569
Email lena.ulm@med.uni-greifswald.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S. aureus bacteraemia (SAB) can improve adherence to our in-house SAB-guidelines (prospective quality- improvement group). In addition, the effects of telephone consultation on the clinical outcome of patients will be examined.


Recruitment information / eligibility

Status Recruiting
Enrollment 124
Est. completion date April 23, 2025
Est. primary completion date January 22, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years - Inpatient treatment at the University Medicine Greifswald university hospital - First diagnosis of SAB in hospital Exclusion Criteria: - SAB already known before admission - Palliative management within 48 hrs after SAB diagnosis - Death within 48 hrs after SAB diagnosis - Hospital discharge within 48hrs after SAB diagnosis

Study Design


Intervention

Other:
Checklist-based phone calls
The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB. On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines. The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines.

Locations

Country Name City State
Germany Greifswald University Medicine Greifswald

Sponsors (1)

Lead Sponsor Collaborator
University Medicine Greifswald

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary SOP adherence, calculated as a sum score per patient with the following 8 parameters: Drawing of follow-up blood cultures 2-3 days after start of adequate antibiotic therapy
Early source control (removal of infected material or drainage of an abscess = 72 hrs)
Adequate search for SAB focus and metastatic manifestations
TEE in patients with clinical indications (within 4 days of SAB diagnosis)
Early start of specific therapy after receipt of results via phone call (=12 hrs)
Adequate dosage of antibiotic
Sufficient duration of therapy (at least 14 d for uncomplicated bacteremia and 28 d for complicated bacteremia)
Combination therapy with Rifampicin or Fosfomycin, when indicated
Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary Time to specific antimicrobial treatment according to guidelines concerning agent and duration Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary Time to negativity of follow up blood cultures Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)
Secondary Time till TEE is performed (when indicated) Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary Length of hospital stay after SAB diagnosis Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)
Secondary In-hospital mortality (all patients) Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary In-hospital mortality (because of SAB complications) Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary Hospital readmission until day 30 after SAB diagnosis (all patients) Day of SAB diagnosis until day 30 after diagnosis
Secondary Hospital readmission until day 30 after SAB diagnosis (because of SAB complications) Day of SAB diagnosis until day 30 after diagnosis
Secondary Hospital readmission until day 90 after SAB diagnosis (all patients) Day of SAB diagnosis until day 90 after diagnosis
Secondary Hospital readmission until day 90 after SAB diagnosis (because of SAB complications) Day of SAB diagnosis until day 90 after diagnosis
Secondary 90-day all-cause mortality Day of SAB diagnosis until day 90 after diagnosis
Secondary 90-day mortality because of SAB complications Day of SAB diagnosis until day 90 after diagnosis
Secondary Relapse of bacteremia until day 90 after diagnosis Day of SAB diagnosis until day 90 after diagnosis
Secondary Quality of discharge summary (documentation and treatment plan), calculated as a sum score Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary Infectious diseases consultation, when indicated (yes/no) Hospital admission until hospital discharge (no later than day 90 after diagnosis)
See also
  Status Clinical Trial Phase
Recruiting NCT05862025 - Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study). N/A
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Recruiting NCT00622882 - Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia N/A
Recruiting NCT06168474 - Evaluating Simplified Layered Consent for Clinical Trials N/A
Completed NCT03163446 - Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia Phase 2
Not yet recruiting NCT06336824 - Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia Phase 3
Completed NCT02357966 - A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus Phase 1/Phase 2
Recruiting NCT04886284 - Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia Phase 2
Terminated NCT03089697 - Phase IIa Clinical Study of N-Rephasin® SAL200 Phase 2
Recruiting NCT03514446 - Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia Phase 4
Withdrawn NCT03761953 - Oritavancin for Staphylococcus Aureus Infections in Opioid Users Phase 4
Recruiting NCT02098850 - Staphylococcus Aureus Bacteraemia in Adults N/A
Completed NCT01701219 - Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia Phase 4
Recruiting NCT05137119 - Staphylococcus Aureus Network Adaptive Platform Trial Phase 4
Completed NCT03908086 - Bloodstream Infections in Patients With Rheumatoid Arthritis
Terminated NCT04160468 - Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase Phase 3
Completed NCT03138733 - Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia Phase 3
Completed NCT02476487 - The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia N/A
Recruiting NCT05184764 - Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia Phase 1/Phase 2
Completed NCT01971762 - Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology N/A